News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Receptos (RCPT) Announces Pricing Of Underwritten Public Offering Of Common Stock



6/19/2014 8:50:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 18, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 4,433,000 shares of its common stock at a price to the public of $40.25 per share. The gross proceeds to Receptos from this offering are expected to be approximately $178.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an aggregate of 664,950 additional shares of common stock. The offering is expected to close on or about June 24, 2014, subject to customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Receptos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES